Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 8/2010

01-08-2010 | Article

IL-6 deficiency in mice neither impairs induction of metabolic genes in the liver nor affects blood glucose levels during fasting and moderately intense exercise

Authors: L. Fritsche, M. Hoene, R. Lehmann, H. Ellingsgaard, A. M. Hennige, A. K. Pohl, H. U. Häring, E. D. Schleicher, C. Weigert

Published in: Diabetologia | Issue 8/2010

Login to get access

Abstract

Aims/hypothesis

Fasting and exercise are strong physiological stimuli for hepatic glucose production. IL-6 has been implicated in the regulation of gluconeogenic genes, but the results are contradictory and the relevance of IL-6 for fasting- and exercise-induced hepatic glucose production is not clear.

Methods

Investigations were performed in rat hepatoma cells, and on C57Bl6 and Il6 −/− mice under the following conditions: IL-6 stimulation/injection, non-exhaustive exercise (60 min run on a treadmill) and fasting for 16 h. Metabolite analysis, quantitative real-time PCR and immunoblotting were performed.

Results

IL-6 stimulation of rat hepatoma cells led to higher glucose production. Injection of IL-6 in mice slightly increased hepatic Pepck (also known as Pck1) expression. Fasting of Il6 −/− mice for 16 h did not alter glucose production compared with wild-type mice, since plasma glucose concentrations were similar and upregulation of phosphoenolpyruvate carboxykinase (PEPCK) and Pgc-1α (also known as Ppargc1a) expression was comparable. In the non-fasting state, Il6 −/− mice showed a mild metabolic alteration including higher plasma glucose and insulin levels, lower NEFA concentrations and slightly increased hepatic PEPCK content. Moderately intense exercise resulted in elevated IL-6 plasma levels in wild-type mice. Despite that, plasma glucose, insulin, NEFA levels and hepatic glycogen content were not different in Il6 −/− mice immediately after running, while expression of hepatic G6pc, Pgc-1α, Irs2 and Igfbp1 mRNA was similarly increased.

Conclusions/interpretation

These data suggest that in mice IL-6 is not essential for physiologically increased glucose production during fasting or non-exhaustive exercise.
Appendix
Available only for authorised users
Literature
1.
2.
Camacho RC, Donahue EP, James FD, Berglund ED, Wasserman DH (2006) Energy state of the liver during short-term and exhaustive exercise in C57BL/6J mice. Am J Physiol Endocrinol Metab 290:E405–E408CrossRefPubMed
3.
Kjaer M (1998) Hepatic glucose production during exercise. Adv Exp Med Biol 441:117–127PubMed
4.
Christ B, Nath A, Heinrich PC, Jungermann K (1994) Inhibition by recombinant human interleukin-6 of the glucagon-dependent induction of phosphoenolpyruvate carboxykinase and of the insulin-dependent induction of glucokinase gene expression in cultured rat hepatocytes: regulation of gene transcription and messenger RNA degradation. Hepatology 20:1577–1583CrossRefPubMed
5.
Inoue H, Ogawa W, Ozaki M et al (2004) Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med 10:168–174CrossRefPubMed
6.
Lienenluke B, Christ B (2007) Impact of interleukin-6 on the glucose metabolic capacity in rat liver. Histochem Cell Biol 128:371–377CrossRefPubMed
7.
Metzger S, Goldschmidt N, Barash V et al (1997) Interleukin-6 secretion in mice is associated with reduced glucose-6-phosphatase and liver glycogen levels. Am J Physiol 273:E262–E267PubMed
8.
Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1–20CrossRefPubMed
9.
Ramadoss P, Unger-Smith NE, Lam FS, Hollenberg AN (2009) STAT3 targets the regulatory regions of gluconeogenic genes in vivo. Mol Endocrinol 23:827–837CrossRefPubMed
10.
Blumberg D, Hochwald S, Brennan MF, Burt M (1995) Interleukin-6 stimulates gluconeogenesis in primary cultures of rat hepatocytes. Metabolism 44:145–146CrossRefPubMed
11.
Leu JI, Crissey MA, Leu JP, Ciliberto G, Taub R (2001) Interleukin-6-induced STAT3 and AP-1 amplify hepatocyte nuclear factor 1-mediated transactivation of hepatic genes, an adaptive response to liver injury. Mol Cell Biol 21:414–424CrossRefPubMed
12.
Ritchie DG (1990) Interleukin 6 stimulates hepatic glucose release from prelabeled glycogen pools. Am J Physiol 258:E57–E64PubMed
13.
Vaartjes WJ, de Haas CG, Houweling M (1990) Acute effects of interleukin 1 alpha and 6 on intermediary metabolism in freshly isolated rat hepatocytes. Biochem Biophys Res Commun 169:623–628CrossRefPubMed
14.
Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP (1997) Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 82:4167–4170CrossRefPubMed
15.
Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Klarlund PB (2000) Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 529:237–242CrossRefPubMed
16.
Penkowa M, Keller C, Keller P, Jauffred S, Pedersen BK (2003) Immunohistochemical detection of interleukin-6 in human skeletal muscle fibers following exercise. FASEB J 17:2166–2168PubMed
17.
Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK (2004) Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 53:1643–1648CrossRefPubMed
18.
Faldt J, Wernstedt I, Fitzgerald SM, Wallenius K, Bergstrom G, Jansson JO (2004) Reduced exercise endurance in interleukin-6-deficient mice. Endocrinology 145:2680–2686CrossRefPubMed
19.
Weigert C, Hennige AM, Lehmann R et al (2006) Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. J Biol Chem 281:7060–7067CrossRefPubMed
20.
Chan TM, Exton JH (1976) A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes. Anal Biochem 71:96–105CrossRefPubMed
21.
Hiscock N, Chan MH, Bisucci T, Darby IA, Febbraio MA (2004) Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity. FASEB J 18:992–994PubMed
22.
Rosendal L, Sogaard K, Kjaer M, Sjogaard G, Langberg H, Kristiansen J (2004) Increase in interstitial interleukin-6 of human skeletal muscle with repetitive low-force exercise. J Appl Physiol 182:379–388
23.
Helge JW, Stallknecht B, Pedersen BK, Galbo H, Kiens B, Richter EA (2003) The effect of graded exercise on IL-6 release and glucose uptake in human skeletal muscle. J Physiol 546:299–305CrossRefPubMed
24.
Carey AL, Steinberg GR, Macaulay SL et al (2006) Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55:2688–2697CrossRefPubMed
25.
Glund S, Deshmukh A, Long YC et al (2007) IL-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes 56:1630–1637CrossRefPubMed
26.
Al Khalili L, Bouzakri K, Glund S, Lonnqvist F, Koistinen HA, Krook A (2006) Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol 20:3364–3375CrossRefPubMed
27.
Bruce CR, Dyck DJ (2004) Cytokine regulation of skeletal muscle fatty acid metabolism: effect of interleukin-6 and tumor necrosis factor-α. Am J Physiol Endocrinol Metab 287:E616–E621CrossRefPubMed
28.
van Hall G, Steensberg A, Sacchetti M et al (2003) Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88:3005–3010CrossRefPubMed
29.
Ruderman NB, Keller C, Richard AM et al (2006) Interleukin-6 regulation of AMP-activated protein kinase: potential role in the systemic response to exercise and prevention of the metabolic syndrome. Diabetes 55(Suppl 2):S48–S54CrossRefPubMed
30.
Banzet S, Koulmann N, Simler N et al (2009) Control of gluconeogenic genes during intense/prolonged exercise: hormone-independent effect of muscle-derived IL-6 on hepatic tissue and PEPCK mRNA. J Appl Physiol 107:1830–1839CrossRefPubMed
31.
Weigert C, Duefer M, Simon P et al (2007) Upregulation of IL-6 mRNA by IL-6 in skeletal muscle cells: role of IL-6 mRNA stabilization and Ca2+-dependent mechanisms. Am J Physiol Cell Physiol 293:C1139–C1147CrossRefPubMed
32.
Huang CC, Lin WT, Hsu FL, Tsai PW, Hou CC (2009) Metabolomics investigation of exercise-modulated changes in metabolism in rat liver after exhaustive and endurance exercises. Eur J Appl Physiol 108:557–566CrossRefPubMed
33.
Aldeguer X, Debonera F, Shaked A et al (2002) Interleukin-6 from intrahepatic cells of bone marrow origin is required for normal murine liver regeneration. Hepatology 35:40–48CrossRefPubMed
34.
Cressman DE, Greenbaum LE, DeAngelis RA et al (1996) Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274:1379–1383CrossRefPubMed
35.
Li W, Liang X, Leu JI, Kovalovich K, Ciliberto G, Taub R (2001) Global changes in interleukin-6-dependent gene expression patterns in mouse livers after partial hepatectomy. Hepatology 33:1377–1386CrossRefPubMed
36.
Kubota N, Kubota T, Itoh S et al (2008) Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signaling during fasting and feeding. Cell Metab 8:49–64CrossRefPubMed
37.
Anthony TG, Anthony JC, Lewitt MS, Donovan SM, Layman DK (2001) Time course changes in IGFBP-1 after treadmill exercise and postexercise food intake in rats. Am J Physiol Endocrinol Metab 280:E650–E656PubMed
38.
Hoene M, Lehmann R, Hennige AM et al (2009) Acute regulation of metabolic genes and insulin receptor substrates in the liver of mice by one single bout of treadmill exercise. J Physiol 587:241–252CrossRefPubMed
39.
Konner AC, Janoschek R, Plum L et al (2007) Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production. Cell Metab 5:438–449CrossRefPubMed
40.
Inoue H, Ogawa W, Asakawa A et al (2006) Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab 3:267–275CrossRefPubMed
41.
Ellingsgaard H, Ehses JA, Hammar EB et al (2008) Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci U S A 105:13163–13168CrossRefPubMed
42.
Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA (2004) Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am J Physiol Endocrinol Metab 287:E182–E187CrossRefPubMed
43.
Wallenius V, Wallenius K, Ahren B et al (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8:75–79CrossRefPubMed
44.
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327–334CrossRefPubMed
45.
Fernandez-Real JM, Vayreda M, Richart C et al (2001) Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86:1154–1159CrossRefPubMed
46.
Cardellini M, Perego L, D'Adamo M et al (2005) C-174G polymorphism in the promoter of the interleukin-6 gene is associated with insulin resistance. Diabetes Care 28:2007–2012CrossRefPubMed
47.
Allen TL, Febbraio MA (2010) IL-6 as a mediator of insulin resistance: fat or fiction? Diabetologia 53:399–402CrossRefPubMed
Metadata
Title
IL-6 deficiency in mice neither impairs induction of metabolic genes in the liver nor affects blood glucose levels during fasting and moderately intense exercise
Authors
L. Fritsche
M. Hoene
R. Lehmann
H. Ellingsgaard
A. M. Hennige
A. K. Pohl
H. U. Häring
E. D. Schleicher
C. Weigert
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 8/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1754-4

Other articles of this Issue 8/2010

Diabetologia 8/2010 Go to the issue

Article

Reciprocal modulation of adult beta cell maturity by activin A and follistatin

Commentary

Cancer and diabetes: are we ready for prime time?

Article

Exercise training increases mitochondrial content and ex vivo mitochondrial function similarly in patients with type 2 diabetes and in control individuals

Article

Beta cell-specific Znt8 deletion in mice causes marked defects in insulin processing, crystallisation and secretion

Article

Cardiovascular disease risk factors, depression symptoms and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes

Erratum

Erratum to: Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits